多发性骨髓瘤中对T细胞衔接双特异性抗体耐药的机制:对新型治疗策略的启示
该综述聚焦靶向BCMA、GPRC5D和FcRH5的现成T细胞重定向双特异性抗体在多发性骨髓瘤中的耐药机制,涵盖肿瘤相关因素、T细胞功能障碍及免疫抑制微环境,并探讨三特异性抗体、双特异性抗体联合及靶向T细胞耗竭通路等优化策略。
要点
- 双特异性抗体耐药机制多因素,包括高肿瘤负荷、T细胞抑制配体表达和抗原丢失。
- 同时靶向两种肿瘤相关抗原(三特异性抗体或双特异性抗体联合)可能预防抗原逃逸所致耐药。
- 靶向抑制性或共刺激通路以干预T细胞耗竭,或可改善双特异性抗体介导的抗肿瘤活性。
核心结论
- 更好地理解疾病无反应机制为优化多发性骨髓瘤中T细胞活性和双特异性抗体疗效提供了新见解。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 靶向BCMA、GPRC5D和FcRH5的现成T细胞重定向双特异性抗体在多发性骨髓瘤中活性高且毒性可控。
- 并非所有患者对双特异性抗体有反应,且初始反应后可出现耐药。
- 耐药机制多因素,包括高肿瘤负荷、T细胞抑制配体表达和抗原丢失等肿瘤相关因素。
- 越来越多证据表明原发性耐药与基线T细胞功能受损相关,长期暴露致慢性T细胞刺激加重T细胞功能障碍。
- 免疫抑制微环境也促进耐药,靶向CD38抗体因可消除CD38+免疫抑制细胞而有潜力作为联合伙伴。
关键数值与推荐
- 同时靶向两种肿瘤相关抗原(三特异性抗体或两种双特异性抗体联合)可预防抗原逃逸所致耐药。
- 靶向抑制性或共刺激通路干预T细胞耗竭或可改善双特异性抗体介导的抗肿瘤活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Off-the-shelf T-cell-redirecting bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 have high activity in multiple myeloma with a manageable toxicity profile. However, not all patients respond to bispecific antibodies and patients can develop bispecific antibody resistance after an initial response. Mechanisms that contribute to bispecific antibody resistance are multifactorial and include tumour-related factors, such as high tumour burden, expression of T-cell inhibitory ligands, and antigen loss. Resistance due to antigen escape can be prevented by simultaneously targeting two tumour-associated antigens with a trispecific antibody or a combination of two bispecific antibodies. There is also increasing evidence that primary resistance to bispecific antibodies is associated with impaired baseline T-cell function. Long-term exposure to bispecific antibodies with chronic T-cell stimulation further aggravates T-cell dysfunction, which could contribute to failure of disease control. Therapeutic interference with T-cell exhaustion by targeting inhibitory or costimulatory pathways could improve bispecific antibody-mediated antitumour activity. The immunosuppressive microenvironment also contributes to bispecific antibody resistance. CD38-targeting antibodies hold promise as combination partners for bispecific antibodies because of their potential to eliminate CD38+ immune suppressor cells. In conclusion, a better understanding of the mechanisms underlying the absence of disease response has provided novel insights to optimise T-cell activity and bispecific antibody efficacy in multiple myeloma.
引用
- van de Donk NWCJ, Chari A, Mateos MV, et al. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024. PMID: 39033769. doi:10.1016/S2352-3026(24)00186-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。